TRIANA Biomedicines Secures $120M Series B to Advance ALK-Targeted Molecular Glue Degrader for Lung Cancer
核心洞察
TRIANA Biomedicines (搜索) closed an oversubscribed $120 million Series B financing round co-led by Ascenta Capital (搜索) and Bessemer Venture Partners (搜索) to advance its molecular glue degrader (搜索) pipeline.
The funding will support development of lead candidate TRI-611 (搜索), an ALK (搜索)-targeted molecular glue degrader (搜索), to clinical proof of concept in ALK-positive non-small cell lung cancer (搜索) patients.
TRI-611 (搜索) is designed to address acquired resistance and tolerability issues that remain key challenges with current ALK tyrosine kinase inhibitor (搜索) therapies in this predominantly younger lung cancer (搜索) population.
TRIANA Biomedicines (搜索) has successfully closed an oversubscribed $120 million Series B financing round to advance its lead molecular glue degrader (搜索) TRI-611 (搜索) toward clinical proof of concept in ALK-positive non-small cell lung cancer (搜索) (NSCLC). The Lexington, Massachusetts-based biotechnology company announced the funding will support development of its anaplastic lymphoma kinase (搜索) (ALK (搜索))-targeted therapy and accelerate maturation of multiple pipeline programs.
The Series B financing was co-led by new investors Ascenta Capital (搜索) and Bessemer Venture Partners (搜索), with additional new investors including YK Bioventures, Regeneron Ventures (搜索), Invus, and Finchley Healthcare Ventures. Existing founding investors RA Capital Management and Atlas Venture continued their support, along with Lightspeed Venture Partners, Pfizer Ventures (搜索), and Surveyor Capital.
Addressing Unmet Medical Need in ALK+ NSCLC
While advances in ALK tyrosine kinase inhibitor (搜索) therapies have markedly improved outcomes for patients with ALK (搜索)+ NSCLC, acquired resistance and tolerability issues remain key challenges in this predominantly younger lung cancer (搜索) subpopulation. TRIANA's approach with TRI-611 (搜索) presents a significant opportunity to advance the standard of care and improve the lives of patients living with ALK+ NSCLC.
"Successful closing of our Series B fundraising represents a major milestone in TRIANA's mission to innovate therapies for difficult to treat cancers," said Dr. Patrick Trojer, President and CEO of TRIANA. "We are pleased to have the strong backing of world-class investors and thank both our new and existing partners for their commitment to advancing our mission. We look forward to the clinical development of TRI-611 (搜索) for lung cancer (搜索) patients."
Molecular Glue Platform Technology
TRIANA's drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights, and high-resolution structural biology. The company's target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile cancer targets.
"We've long viewed molecular glues as one of the most promising frontiers in targeted protein degradation," said Andrew Hedin, Partner at Bessemer Venture Partners (搜索). "We've followed TRIANA closely as their world-class team has built a leading discovery engine to unlock this next-generation modality and deliver new therapies to patients. Their rapid execution and lead ALK (搜索)+ non-small cell lung cancer (搜索) program designed to overcome resistance seen with current treatments reflect the kind of bold, science-driven innovation that can transform patient outcomes."
Clinical Development Timeline
The proceeds from the financing will support development of TRI-611 (搜索) to clinical proof of concept in ALK (搜索)+ NSCLC patients and enable selection of a second product candidate in 2026. The funding will also advance TRIANA's product pipeline beyond TRI-611.
"We are impressed by TRIANA's platform, with its target-first approach to rational molecular-glue design, and TRI-611 (搜索), that selectively degrades ALK (搜索) variants with a compelling pharmacologic profile," said Dr. Lorence Kim, Managing Partner and Co-Founder of Ascenta Capital (搜索). "At Ascenta, we are drawn to platforms that unite deep mechanistic insight with clear clinical potential, and we look forward to supporting TRIANA as it grows to support a full clinical development effort to bring medicines closer to patients."
In association with the Series B financing, Dr. Lorence Kim from Ascenta Capital (搜索) and Andrew Hedin of Bessemer Venture Partners (搜索) will join TRIANA's Board of Directors. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients with difficult-to-drug disease targets.